Modulation of sympathetic control by ACE inhibitors

Area of Science:

• Pharmacology
• Cardiovascular Physiology
• Neuroendocrinology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors modulate the renin-angiotensin-aldosterone system.
• ACE also metabolizes bradykinin, a peptide that influences catecholamine release.
• Potential indirect effects of ACE inhibitors on sympathetic nervous system function are not fully understood.

Purpose of the Study:

• To investigate the impact of ACE inhibition on catecholamine (noradrenaline and adrenaline) release.
• To examine the role of angiotensin I and bradykinin in modulating catecholamine release during ACE inhibition.
• To assess the effect of ramipril, an ACE inhibitor, on noradrenaline reuptake.

Main Methods:

• Evaluation of catecholamine biosynthesis, storage, and release under chronic ACE inhibition.
• Assessment of noradrenaline reuptake mechanisms in the presence of ramipril.
• Dose-dependent studies of angiotensin I and bradykinin effects on noradrenaline release during ACE inhibition.

Main Results:

• Chronic ACE inhibition did not alter catecholamine biosynthesis, storage, or release.
• Ramipril significantly diminished noradrenaline reuptake.
• Bradykinin, but not angiotensin I, dose-dependently stimulated noradrenaline release during ACE inhibition.

Conclusions:

• ACE inhibitors do not directly affect catecholamine release but can alter noradrenaline reuptake.
• Bradykinin plays a significant role in modulating noradrenaline release under ACE inhibition.
• Bradykinin may compensate for the lack of direct effect of ACE inhibitors on catecholamine release.